Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | BCHE | P06276 | 3/20 | 0.72 |
| ▸ | ACHE | P22303 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239436 | 0.87 | BCHE (0.78) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL11171388 | 0.85 | BCHE (0.75) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL2086851 | 0.83 | BCHE (0.67) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL8428842 | 0.83 | MEN1 (0.78) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL4452339 | 0.82 | BCHE (0.72) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL8870414 | 0.81 | NOX1 (0.73) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL14697644 | 0.80 | BCHE (0.63) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL28628271 | 0.79 | BCHE (1.00) | MEN1KMT2ABCHEACHEALDH1A1 | |
| SCHEMBL14291953 | 0.79 | BCHE (0.89) | MEN1KMT2ABCHEACHEALDH1A1 | |
| Chloracyzine SCHEMBL309939 | 0.79 | ALDH1A1 (0.77) | MEN1KMT2ABCHEACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | MEN1 3926/4885KMT2A 2304/4885BCHE 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.